Drug

Mitomycin

In clinical development

Emerging researchLate-stage development

Also known as 7-Amino-9alpha-methoxymitosane, Jelmyto, MMC, MMC-Mitomycin-C+10 more

7-Amino-9alpha-methoxymitosane, Jelmyto, MMC, MMC-Mitomycin-C, Mito-C, MitoMYcin Ophthalmic, Mitosol, Zusduri, Mutamycin, Mitamycin, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C.

RxNorm632 ChEMBLCHEMBL105 ATCL01DC03UNII50SG953SK6

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

Clinical trial2026-07-31Results expected Q1 2032 · ClinicalTrials.gov

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Clinical trial2026-07-10Results expected Q4 2029 · ClinicalTrials.gov

A Multicenter, Phase III, Randomized Controlled Clinical Trial of Sintilimab Versus Mitomycin in Combination With Capecitabine and Intensity-Modulated Radiotherapy in the Treatment of Limited-stage Anal Squamous Cell Carcinoma

Clinical trial2026-07-09Results expected Q1 2029 · ClinicalTrials.gov

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries

Clinical trial2026-07-08Results expected Q4 2033 · ClinicalTrials.gov

17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)

Clinical trial2026-07-07Results expected Q4 2030 · ClinicalTrials.gov

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations

Clinical trial2026-07-06Results expected Q2 2028 · ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

Clinical trial2026-07-06Results expected Q2 2028 · ClinicalTrials.gov

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

Clinical trial2026-07-02Results expected Q1 2030 · ClinicalTrials.gov

A Phase II Single Arm Study of Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

Clinical trial2026-07-02Results expected Q2 2030 · ClinicalTrials.gov

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Clinical trial2026-07-02Results expected Q2 2027 · ClinicalTrials.gov

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.

Research2023-11-08Annals of surgical oncology

A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.

Research2014-02-03International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Mitomycin

Aliases & brands

7-Amino-9alpha-methoxymitosaneJelmytoMMCMMC-Mitomycin-CMito-CMitoMYcin OphthalmicMitosolZusduriMutamycinMitamycinMitomycin CMitomycin-CMitomycin-XMitomycine C

RxNorm CUI

632

ChEMBL ID

CHEMBL105

ATC codes

L01DC03

UNII

50SG953SK6

Clinical trials

158 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

158

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 158

Early Phase 14Phase 119Phase 1 / 28Phase 257Phase 2 / 37Phase 344Phase 411Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

RecruitingPH IVJakob Kristian Jakobsenn=2722032

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

CompletedPH IVJørgen Bjerggaard Jensenn=1202025

A Prospective Randomized Clinical Trial Comparing Three Delivery Methods of Mitomycin-C for Trabeculectomy Surgery: Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Topical Application (Conventional Use) During Trabeculectomy Surgery

TerminatedPH IVUniversity of California, Los Angelesn=192022

Primary Tube Versus Trabeculectomy Study

CompletedPH IVUniversity of Miamin=2422021

The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer

Unknown statusPH IVAzienda Ospedaliera "Sant'Andrea"n=1402021

Recent completions

Trials that read out recently, adding to the completed evidence base.

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

CompletedPH IVJørgen Bjerggaard Jensenn=1202025

A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

CompletedPH IIFox Chase Cancer Centern=782025

Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

CompletedPH IIWashington University School of Medicinen=482024

Phase II Trial of Cytoreduction + Hyperthermic Intraperitoneal Mitomycin-C+ Standard Systemic Therapy In Patients With Peritoneal Carcinomatosis

CompletedPH IIAlbert Einstein College of Medicinen=512024

Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

CompletedPH IINational Cancer Institute (NCI)n=272024

Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture

CompletedPH II/IIIAin Shams Universityn=502023

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20142024

Most influential

A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2014 · 48 cites

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.

Annals of surgical oncology · 2024 · 27 cites